搜尋結果
2024年1月9日 · The U.S. Food and Drug Administration (FDA) granted traditional approval on July 6, 2023. In the U.S., treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reconfirmed today that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name: lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.
其他人也問了
Who is Miguel Gutierrez?
Who is Ms. Gutierrez?
Who is Dr Miguel Gutierrez - Diaz?
Who is Dr. Michael E. Gutierrez?
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.
for Early Alzheimer’s Disease in the European Union. TOKYO and CAMBRIDGE, Mass., July 26, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Committee for Medicinal ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) in the first quarter of fiscal year 2024 (April 1, 2024 – June 30, 2024) was JPY 6.3 billion (pre-audit basis), which was approximately 2.2 times higher than t...
Eisai developed this product with the review of a physician as an easy and fun introductory exercise for those concerned about their brain health. It is being used in health classes and online events run by local governments.
Eisai Co., Ltd. announced that the following Directors and Corporate Officers for FY2024 were appointed by resolutions at the 112th Ordinary General Meeting of Shareholders and subsequent Board of Directors meeting held today. Directors (*Outside Directors) Board of Directors.
